Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Deputy Asia Editor
{552A1C46-4F5F-49D4-95ED-3A30B4BA2693}
+18 year(s) experience
Anju has extensive experience at India's mainstream financial dailies, The Economic Times, The Hindu Business Line and The Financial Express. As Corporate Bureau Chief (Mumbai), she led a team of reporters at The Financial Express prior to joining Scrip. She’s been associated with Scrip since 2001, when it was part of PJB Publications.
Anju enjoys covering pharma conferences and interviewing industry heads and regulatory/government officials in the region. Occasionally, she also moderates industry panels at key events.
She follows racket sports closely and has previously received recognition at the national level in India. She loves the hills and when not reporting on pharma believes that nature is the best therapy.
Generics Bulletin
By Anju Ghangurde 26 Jul 2019
More Indian companies are headed to China, with Cipla the latest to seal a joint venture there, though the firm has previous links with the country. Respiratory products will lead Cipla’s line-up in China, a market seen as a crucial cog in the firm’s future road map.
Pink Sheet
By Anju Ghangurde 28 May 2019
Courts may increasingly find limits on how far Park Doctrine tool can be ‘pushed,’ Sklamberg says in wide-ranging interview with the Pink Sheet. Former US FDA deputy commissioner for global regulatory operations and policy, now with law firm Akin Gump, also shares his views on the US-EU MRA to recognize each other’s inspections and data integrity.
Topic FDA
Scrip
By Anju Ghangurde 07 Mar 2019
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
Scrip
By Anju Ghangurde 20 Sep 2018
Almirall's Ilumetri, licensed from Sun Pharma, has been cleared by the European Commission, upping the competition quotient in the psoriasis market and pitting the product directly against Johnson & Johnson's Tremfya.
Topic BioPharmaceutical
Scrip
By Anju Ghangurde 22 Aug 2018
Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.
Topic Strategy
Scrip
By Anju Ghangurde 31 Jan 2018
IQVIA’s general manager (South Asia), Amit Mookim, outlines the reasons for scaling down the five-year outlook for the Indian pharmaceutical market, including a near halving of the prognosis for 2017.
Topic Company analysis
Scrip
By Anju Ghangurde 18 Jan 2018
US scale-up plans, cost optimization and a deeper push in certain other markets to garner volumes and as a buffer against volatility were some of the key strategies discussed by Cipla’s CEO
Topic Strategy
Topic Infectious diseases
Scrip
By Anju Ghangurde 21 Nov 2017
The Indian contract development and manufacturing organization Piramal Pharma Solutions expects to grow its pool of “preferred partnerships” that includes a mix of both biotechs and large pharma.
Scrip
By Anju Ghangurde 16 Nov 2017
Lara Bezerra moves from turbulent Venezuela to head Roche in India. Scrip highlights what the incoming Roche boss might expect on the generally peaceful yet complex Indian market.
Scrip
By Anju Ghangurde 16 Nov 2017
Lara Bezerra moves from turbulent Venezuela to head Roche in India. Scrip highlights what the incoming Roche boss might expect on the generally peaceful yet complex Indian market.
Scrip
By Anju Ghangurde 16 Nov 2017
Lara Bezerra moves from turbulent Venezuela to head Roche in India. Scrip highlights what the incoming Roche boss might expect on the generally peaceful yet complex Indian market.
Medtech Insight
By Anju Ghangurde 31 Oct 2017
India's price capping for medical devices is threatening to snowball into a trade tit-for-tat with the US.
Topic Policy and regulation
Scrip
By Anju Ghangurde 14 Feb 2017
Five Big Picture R&D Questions For J&J’s Stoffels, Novartis’s Narasimhan
Scrip
By Anju Ghangurde 23 Jan 2017
The Trump presidency and the threat of protectionism, new generic opportunities beyond the US market, and the need for new quality benchmarks were some of the key issues discussed at the recent annual day celebrations of the Indian Drug Manufacturers’ Association.
Topic Strategy us-election
Scrip
16 Oct 2019
Scrip
16 Oct 2019
Scrip
11 Oct 2019
Scrip
07 Oct 2019
Scrip
03 Oct 2019
Scrip
02 Oct 2019
Scrip
29 Sep 2019
Scrip
24 Sep 2019
Scrip
23 Sep 2019
Scrip
18 Sep 2019
Scrip
17 Sep 2019
Scrip
12 Sep 2019
Scrip
11 Sep 2019
Scrip
09 Sep 2019
Scrip
06 Sep 2019
